Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387694 | 0.83 | TACR1 (0.40) | CYP3A4CYP2C9CYP2C19ELANE | |
| SCHEMBL10583564 | 0.82 | KDM4E (0.48) | KDM4EALDH1A1SMN1; SMN2GAATDP1 | |
| SCHEMBL1675958 | 0.82 | MEN1 (0.39) | ELANE | |
| SCHEMBL29356663 | 0.80 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2GAATDP1 | |
| SCHEMBL29361704 | 0.80 | KDM4E (0.43) | KDM4EALDH1A1SMN1; SMN2GAATDP1 | |
| SCHEMBL2289363 | 0.79 | ELANE (0.42) | ELANE | |
| SCHEMBL29544152 | 0.78 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2GAATDP1 | |
| SCHEMBL8662040 | 0.78 | ELANE (0.40) | ELANE | |
| SCHEMBL8914276 | 0.77 | KDM4E (0.52) | KDM4EALDH1A1SMN1; SMN2GAATDP1 | |
| SCHEMBL228960 | 0.76 | ELANE (0.38) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11992481-B2 | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2024-05-28 | — | — | US | disclosed |
| US-20220249456-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | US | disclosed |
| CN-109152771-B | Use of 2-substituted indazoles for the treatment and prevention of autoimmune diseases | 拜耳医药股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20210085664-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-25 | — | — | US | disclosed |
| US-20190125736-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-02 | — | — | US | disclosed |
| EP-3463354-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2019-04-10 | — | — | EP | disclosed |
| WO-2017207386-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-12-07 | — | — | WO | disclosed |
| WO-2016201528-A1 | TREATMENT OF INFLAMMATION AND/OR CANCER | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2016-12-22 | — | — | WO | disclosed |
| US-20080181892-A1 | Binding Domain Fusion Protein | TRUBION PHARMACEUTICALS (US) | 2008-07-31 | — | — | US | disclosed |
| WO-2007068885-A2 | ACTIVE WOUND DRESSING MATERIALS | ETHICON, INC (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-0475160-B2 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-20030175919-A1 | ITI-D1 Kunitz domain mutants as hNE inhibitors | DYAX CORP. | 2003-09-18 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| EP-0797666-A2 | GENETICALLY ENGINEERED HUMAN-DERIVED KUNITZ DOMAINS THAT INHIBIT HUMAN NEUTROPHIL ELASTASE | Dyax Corp. (US) | 1997-10-01 | — | — | EP | disclosed |
| US-5663143-A | PROTEIN WHICH BINDS AND INHIBITS ELASTASE | DYAX CORP. (US) | 1997-09-02 | — | — | US | disclosed |
| WO-1996020278-A2 | GENETICALLY ENGINEERED HUMAN-DERIVED KUNITZ DOMAINS THAT INHIBIT HUMAN NEUTROPHIL ELASTASE | DYAX CORP. (US) | 1996-07-04 | — | — | WO | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475531-B1 | Benzoic acid phenylester compounds and elastase inhibiting compositions containing the same | ASAHI CHEMICAL IND (JP) | 1995-01-18 | — | — | EP | disclosed |
| EP-0475531-A1 | Benzoic acid phenylester compounds and elastase inhibiting compositions containing the same | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-03-18 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125736-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | IDO2, IL33, IDO1 | KDM4E 1446/4885ALDH1A1 996/4885SMN1; SMN2 3003/4885 |
| US-20210085664-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | IDO2, IL33, IDO1 | KDM4E 1446/4885ALDH1A1 996/4885SMN1; SMN2 3003/4885 |
| US-20220249456-A1 | USE OF 2-SUBSTITUTED INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF AUTOIMMUNE DISEASES | IDO2, IL33, IDO1 | KDM4E 1446/4885ALDH1A1 996/4885SMN1; SMN2 3003/4885 |
| US-11992481-B2 | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases | IDO2, IL33, IDO1 | KDM4E 1446/4885ALDH1A1 996/4885SMN1; SMN2 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.